Abstract
Autophagy plays a key role in the metabolism of macromolecules via the degradative abilities of the lysosome. Transcription factor EB (TFEB) regulates autophagosome biogenesis and lysosome function, and promoting TFEB activity has emerged as a potential strategy for the treatment of metabolic disorders. Herein, we report that cetrimonium bromide (CTAB; a quaternary ammonium compound) promotes autophagy and lysosomal biogenesis by inducing the nuclear translocation of TFEB in hepatic cells. Knockdown of TFEB mediated by short hairpin RNA inhibits CTAB-induced autophagy and lysosomal biogenesis. Mechanistically, CTAB treatment inhibits the Akt-mTORC1 signaling pathway. Moreover, CTAB treatment significantly increases lipid metabolism in both palmitate- and oleate-treated HepG2 cells, and this increase was attenuated by knockdown of TFEB. Collectively, our results indicate that CTAB activates the autophagosome-lysosome pathway via inducing the nuclear translocation of TFEB by inhibiting the mTORC1 signaling pathway. These results add to the collective understanding of TFEB function and provide new insights into CTAB-mediated lipid metabolism.
Introduction
Metabolic disorders, such as non-alcoholic fatty liver disease (NAFLD), are increasingly prevalent and characterized by the toxic accumulation of lipid droplets within cells. Under normal physiological conditions, cells utilize autophagy—a lysosomal degradation pathway—to maintain homeostasis by breaking down macromolecules like lipids. However, in metabolic syndromes, this recycling system often becomes impaired, leading to cellular "clogging."
The master regulator of this recycling system is Transcription Factor EB (TFEB), which orchestrates the biogenesis of autophagosomes and lysosomes. Identifying small molecules capable of activating TFEB to enhance lipid clearance is a primary objective in metabolic research. This study investigates the potential of cetrimonium bromide (CTAB), a quaternary ammonium compound commonly used as an antiseptic, to serve as a pharmacological activator of the TFEB-mediated autophagy pathway in hepatic cells.
Methods
The researchers utilized a combination of molecular and cellular biology techniques to elucidate the effects of CTAB on liver cells:
- Cellular Models: The study employed human liver cancer lines (HepG2 and SMMC-7721) and a normal liver cell line (L02). Initial screening for TFEB activity was performed using HeLa cells stably expressing a TFEB-GFP fusion protein.
- TFEB Localization: Nuclear translocation of TFEB was visualized via fluorescence microscopy to determine the activation state of the transcription factor.
- Genetic Silencing: To confirm the necessity of TFEB, the researchers used short hairpin RNA (shRNA) to knock down TFEB expression and observed the subsequent impact on CTAB-induced effects.
- Lipid Metabolism Assay: To simulate fatty liver conditions, cells were treated with palmitate (PA) and oleate (OA). Lipid accumulation and clearance were quantified using Oil Red O (ORO) staining.
- Signaling Pathway Analysis: Western blotting was conducted to track the phosphorylation states of key proteins within the Akt-mTORC1 signaling axis, identifying the upstream mechanism of TFEB activation.
Key Results
CTAB Induces TFEB Nuclear Translocation and Autophagy
The study found that CTAB (at a concentration of 2.5 μM) significantly induced TFEB nuclear accumulation within 12 to 24 hours. This effect was comparable to that of Torin1, a well-known mTORC1 inhibitor. Furthermore, CTAB treatment increased levels of LC3-II (a marker for autophagosome formation) and decreased levels of p62 (a marker for protein degradation), indicating enhanced autophagic flux.
Mechanism of Action: Inhibition of Akt-mTORC1
Under basal conditions, the protein complex mTORC1 phosphorylates TFEB, sequestering it in the cytoplasm. The researchers demonstrated that CTAB inhibits the Akt-mTORC1 signaling pathway. By reducing mTORC1 activity, CTAB allows TFEB to translocate into the nucleus, where it initiates the transcription of genes involved in lysosomal biogenesis and autophagy.
Enhanced Lipid Clearance is TFEB-Dependent
In hepatic cells "overloaded" with lipids through PA/OA treatment, CTAB significantly reduced the area occupied by lipid droplets. Crucially, when TFEB was silenced using shRNA, CTAB's ability to clear these lipids was abolished. This confirms that TFEB is the essential mediator of CTAB-induced lipid metabolism. Notably, these effects were observed at low concentrations (2.5 μM) with minimal toxicity to healthy L02 liver cells.
Discussion and Conclusion
This research identifies CTAB as a novel activator of the TFEB-autophagy axis, offering a potential therapeutic avenue for metabolic diseases like NAFLD. By repurposing a known compound, the study highlights a specific mechanism—inhibition of the Akt-mTORC1 pathway—that triggers cellular "cleanup" via TFEB.
While these in vitro results are promising, several questions remain. The exact molecular target where CTAB first interacts with the cell to inhibit Akt-mTORC1 is yet to be identified. Additionally, the potential role of phosphatases in TFEB activation alongside mTORC1 inhibition warrants further investigation. Future studies must evaluate the systemic safety and efficacy of CTAB in animal models of obesity and fatty liver disease to determine its clinical viability.
Summary updated